<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>80(4)</volume><submitter>Tellapragada C</submitter><funding>Scilife Pandemic Laboratory Preparedness</funding><pubmed_abstract>&lt;h4>Objectives&lt;/h4>We aimed to investigate the in vitro activity and genetic determinants of decreased susceptibility (DS; MIC > 4 mg/L) to cefepime/zidebactam of carbapenemase-producing Escherichia coli.&lt;h4>Methods&lt;/h4>Clinical isolates (N = 150) of carbapenemase-producing E. coli (CP-EC) belonging to seven distinct STs, isolated at a university clinical microbiology laboratory during 2019-2023 in Stockholm, Sweden were included. MICs for cefepime/zidebactam were determined using the broth microdilution method and interpreted using the tentative EUCAST clinical breakpoints (Susceptible; MIC &lt; 4 mg/L; based on cefepime breakpoint). Whole genome sequences of the isolates were analysed with an emphasis on identifying alterations in PBPs 2 and 3.&lt;h4>Results&lt;/h4>Of the 150 isolates, 145 (96.6%</pubmed_abstract><journal>The Journal of antimicrobial chemotherapy</journal><pagination>1137-1140</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11962383</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Decreased susceptibility to cefepime/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2.</pubmed_title><pmcid>PMC11962383</pmcid><pubmed_authors>Dunleavy C</pubmed_authors><pubmed_authors>Jonsson P</pubmed_authors><pubmed_authors>Giske CG</pubmed_authors><pubmed_authors>Tellapragada C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Decreased susceptibility to cefepime/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2.</name><description>&lt;h4>Objectives&lt;/h4>We aimed to investigate the in vitro activity and genetic determinants of decreased susceptibility (DS; MIC > 4 mg/L) to cefepime/zidebactam of carbapenemase-producing Escherichia coli.&lt;h4>Methods&lt;/h4>Clinical isolates (N = 150) of carbapenemase-producing E. coli (CP-EC) belonging to seven distinct STs, isolated at a university clinical microbiology laboratory during 2019-2023 in Stockholm, Sweden were included. MICs for cefepime/zidebactam were determined using the broth microdilution method and interpreted using the tentative EUCAST clinical breakpoints (Susceptible; MIC &lt; 4 mg/L; based on cefepime breakpoint). Whole genome sequences of the isolates were analysed with an emphasis on identifying alterations in PBPs 2 and 3.&lt;h4>Results&lt;/h4>Of the 150 isolates, 145 (96.6%</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Apr</publication><modification>2025-07-11T03:04:08.248Z</modification><creation>2025-07-11T03:04:08.248Z</creation></dates><accession>S-EPMC11962383</accession><cross_references><pubmed>39960091</pubmed><doi>10.1093/jac/dkaf045</doi></cross_references></HashMap>